BR0116608A - Inibidores vla-4 - Google Patents
Inibidores vla-4Info
- Publication number
- BR0116608A BR0116608A BR0116608-5A BR0116608A BR0116608A BR 0116608 A BR0116608 A BR 0116608A BR 0116608 A BR0116608 A BR 0116608A BR 0116608 A BR0116608 A BR 0116608A
- Authority
- BR
- Brazil
- Prior art keywords
- substituted
- hydroxyl
- salt
- following formula
- single bond
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000000732 arylene group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 abstract 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"INIBIDORES VLA-4". A presente invenção se refere a um composto representado pela fórmula (I) que se segue: onde, W representa W^ A^-A^ 1^-W^ B^- (onde W^ A^ é arila substituída ou não substituída, etc., A^ 1^ representa -NR^ 1^-, uma ligação simples, -C(O)-, etc., e W^ B^ é arileno substituído ou não substituído, etc.), R é uma ligação simples, -NH-, -OCH~ 2~, alquenileno, etc. , X é -C (O) -, -CH~ 2~-, etc. , e M é, por exemplo, a fórmula que se segue: onde, R^ 11^, R^ 12^ e R^ 13^ cada um independentemente representa hidrogênio, hidroxila, amino, halogênio, etc., R^ 14^ é hidrogênio ou alquila inferior, Y representa -CH~ 2~-O-, etc., Z é arileno substituído ou não substituído, etc. , A^ 2^ é uma ligação simples, etc. , e R~ 10~ é hidroxila ou alcóxi inferior ou sal do mesmo; e um medicamento contendo o mesmo. Este composto ou sal do mesmo inibe seletivamente a ligação das moléculas de adesão da célula ao VAL-4 e exibe alta biodisponibilidade, de modo que ele é útil como uma doença preventiva e/ou remédio para doenças inflamatórias, doenças autoimunes, metastase, asma bronquial, rinostenose, diabete e semelhantes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000402890 | 2000-12-28 | ||
JP2001149923 | 2001-05-18 | ||
PCT/JP2001/011641 WO2002053534A1 (fr) | 2000-12-28 | 2001-12-28 | Inhibiteurs de vla-4 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0116608A true BR0116608A (pt) | 2004-06-29 |
Family
ID=26607210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0116608-5A BR0116608A (pt) | 2000-12-28 | 2001-12-28 | Inibidores vla-4 |
Country Status (17)
Country | Link |
---|---|
US (1) | US7157487B2 (pt) |
EP (1) | EP1346982B1 (pt) |
JP (1) | JP4212358B2 (pt) |
KR (1) | KR100884877B1 (pt) |
CN (1) | CN100471838C (pt) |
AR (1) | AR035218A1 (pt) |
AT (1) | ATE524441T1 (pt) |
AU (1) | AU2002219555B2 (pt) |
BR (1) | BR0116608A (pt) |
CA (1) | CA2430978C (pt) |
HK (2) | HK1060726A1 (pt) |
IL (1) | IL156064A0 (pt) |
MX (1) | MXPA03005838A (pt) |
NO (1) | NO326014B1 (pt) |
RU (1) | RU2290403C2 (pt) |
TW (1) | TWI312779B (pt) |
WO (1) | WO2002053534A1 (pt) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0031315D0 (en) * | 2000-12-21 | 2001-02-07 | Glaxo Group Ltd | Indole derivatives |
DE60329910D1 (de) * | 2002-03-29 | 2009-12-17 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
MXPA05003391A (es) * | 2002-10-03 | 2005-06-22 | Hoffmann La Roche | Indol-3-carboxamidas como activadores de glucocinasa. |
US20070066577A1 (en) * | 2003-04-03 | 2007-03-22 | Hea Young Park Choo | Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same |
WO2004099136A1 (ja) * | 2003-05-09 | 2004-11-18 | Daiichi Pharmaceutical Co., Ltd. | ピロリジン誘導体の製造方法 |
EP1479675A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
ES2382806T3 (es) | 2003-07-24 | 2012-06-13 | Daiichi Sankyo Company, Limited | Compuesto ácido ciclohexanocarboxílico |
US6984652B2 (en) | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
WO2005066124A1 (ja) * | 2003-12-26 | 2005-07-21 | Daiichi Pharmaceutical Co., Ltd. | ピロリジン誘導体の製造法 |
US20070149606A1 (en) * | 2003-12-26 | 2007-06-28 | Daiichi Pharmaceutical Co.,Ltd. | Process for producing phenylacetic acid derivative |
BRPI0509150B8 (pt) * | 2004-03-24 | 2021-05-25 | Jerini Ag | compostos para a inibição de angiogênese e uso destes |
JP2005350417A (ja) * | 2004-06-11 | 2005-12-22 | Dai Ichi Seiyaku Co Ltd | 還元的エーテル化法を用いたピロリジン誘導体の製造法 |
TW200610754A (en) * | 2004-06-14 | 2006-04-01 | Daiichi Seiyaku Co | Vla-4 inhibitor |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US8013006B2 (en) | 2004-07-14 | 2011-09-06 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
EP1781289A1 (en) | 2004-07-22 | 2007-05-09 | PTC Therapeutics, Inc. | Thienopyridines for treating hepatitis c |
JP2006056830A (ja) * | 2004-08-20 | 2006-03-02 | Dai Ichi Seiyaku Co Ltd | 2−アリールアミノベンゾオキサゾール誘導体 |
JP2008520744A (ja) * | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
AU2006282403B2 (en) * | 2005-08-26 | 2011-07-07 | Institute Of Medicinal Molecular Design, Inc. | Derivative having PPAR agonistic activity |
US8129366B2 (en) | 2005-12-13 | 2012-03-06 | Daiichi Sankyo Company, Limited | VLA-4 inhibitory drug |
MX2008012929A (es) | 2006-04-04 | 2008-12-17 | Univ California | Antagonistas de cinasa. |
DE102006021878A1 (de) * | 2006-05-11 | 2007-11-15 | Sanofi-Aventis | Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7858645B2 (en) * | 2006-11-01 | 2010-12-28 | Hoffmann-La Roche Inc. | Indazole derivatives |
US20110160232A1 (en) * | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
SG187425A1 (en) | 2008-01-04 | 2013-02-28 | Intellikine Llc | Certain chemical entities, compositions and methods |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
JP5547099B2 (ja) * | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | キナーゼ阻害剤および使用方法 |
WO2010006072A2 (en) * | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
JP5788316B2 (ja) | 2008-07-08 | 2015-09-30 | インテリカイン, エルエルシー | キナーゼインヒビターおよび使用方法 |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
CA2740885C (en) | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
EP4059932A1 (en) | 2008-12-19 | 2022-09-21 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
WO2010129816A2 (en) | 2009-05-07 | 2010-11-11 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
CA2765053C (en) | 2009-06-09 | 2015-08-18 | California Capital Equity, Llc | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
CN102573484B (zh) | 2009-06-09 | 2015-07-01 | 加利福尼亚资本权益有限责任公司 | 苄基取代的三嗪衍生物及其治疗应用 |
JP5785940B2 (ja) | 2009-06-09 | 2015-09-30 | アブラクシス バイオサイエンス, エルエルシー | トリアジン誘導体類及びそれらの治療応用 |
WO2011020874A1 (en) | 2009-08-20 | 2011-02-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
CA2778115C (en) | 2009-10-28 | 2016-04-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
CA2799579A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
RU2014111823A (ru) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ[3,4−d]ピリミジンおよびその用途 |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
CN104995192A (zh) | 2012-09-26 | 2015-10-21 | 加利福尼亚大学董事会 | Ire1的调节 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2016012021A (es) | 2014-03-19 | 2017-04-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2016071499A1 (en) * | 2014-11-06 | 2016-05-12 | Basf Se | 3-pyridyl heterobicyclic compound for controlling invertebrate pests |
SG10201911849SA (en) | 2015-06-09 | 2020-01-30 | Abbvie Inc | Nuclear receptor modulators |
EP3350183A1 (en) | 2015-09-14 | 2018-07-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AU2017281797A1 (en) | 2016-06-24 | 2019-01-24 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CN112969687A (zh) | 2018-10-30 | 2021-06-15 | 吉利德科学公司 | 作为α4β7整合素抑制剂的喹啉衍生物 |
WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
US11174256B2 (en) | 2018-10-30 | 2021-11-16 | Gilead Sciences, Inc. | Imidazopyridine derivatives |
CA3148613A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin |
AU2021289665A1 (en) | 2020-06-10 | 2022-12-15 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
EP4284947A1 (en) | 2021-01-29 | 2023-12-06 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
CA3224494A1 (en) | 2021-07-09 | 2023-01-12 | Koen Vandyck | Anti-viral compounds |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
DE2500157C2 (de) * | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung |
DE2706977A1 (de) * | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
US4184658A (en) | 1978-02-13 | 1980-01-22 | General Electric Company | Cushion mount for prime mover |
DE3063878D1 (en) | 1979-07-13 | 1983-07-28 | Thomae Gmbh Dr K | Derivatives of carboxylic acids, their preparation and medicaments containing them |
JPS60181081A (ja) | 1984-02-29 | 1985-09-14 | Kaken Pharmaceut Co Ltd | 新規ビスベンゾフラニルケトン誘導体 |
JPH04112868A (ja) | 1990-09-03 | 1992-04-14 | Otsuka Pharmaceut Co Ltd | 置換ヘテロ環を有するフェニルカルボン酸誘導体 |
JPH0543574A (ja) | 1991-08-13 | 1993-02-23 | Wakamoto Pharmaceut Co Ltd | ヘテロ環置換テトラゾール−1−酢酸誘導体 |
FR2694295B1 (fr) | 1992-07-28 | 1994-09-02 | Adir | Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent. |
US5821231A (en) | 1993-12-06 | 1998-10-13 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using same |
ES2103181B1 (es) * | 1994-08-01 | 1998-04-01 | Menarini Lab | Amidas naftalenicas con accion antagonista de los leucotrienos. |
GB9408936D0 (en) | 1994-05-05 | 1994-06-22 | Cancer Res Inst | Anti-cancer compounds |
US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
AU6405596A (en) * | 1995-06-30 | 1997-02-05 | Smithkline Beecham Corporation | Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
PL190866B1 (pl) | 1996-07-25 | 2006-02-28 | Biogen | Inhibitor adhezji komórek, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania |
CA2264020A1 (en) | 1996-08-26 | 1998-03-05 | Jean Bemis | Inhibitors of phospholipase enzymes |
DE19647381A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
CN1237960A (zh) | 1996-11-22 | 1999-12-08 | 伊兰药品公司 | N(-芳基/杂芳基乙酰基)氨基酸酯、包括这些酯的药用组合物以及用这些化合物抑制β淀粉样肽释放和/或合成的方法 |
US6117901A (en) * | 1996-11-22 | 2000-09-12 | Athena Neurosciences, Inc. | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use |
CZ20002342A3 (cs) | 1997-12-23 | 2001-11-14 | Aventis Pharma Limited | Substituované ß-alaniny |
CA2322163A1 (en) | 1998-02-25 | 1999-09-02 | John Mckew | Inhibitors of phospholipase a2 |
NZ509199A (en) | 1998-05-28 | 2003-10-31 | Biogen Inc | A VLA-4 inhibitor: oMePUPA-V |
WO1999064392A1 (fr) * | 1998-06-08 | 1999-12-16 | Ajinomoto Co., Inc. | Derive de benzamidine |
WO2000000477A1 (en) | 1998-06-30 | 2000-01-06 | Pfizer Products Inc. | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
EP1133484A2 (en) * | 1998-07-23 | 2001-09-19 | AstraZeneca AB | Heterocyclic derivatives and their use as integrin inhibitors |
GB9916374D0 (en) | 1998-07-23 | 1999-09-15 | Zeneca Ltd | Chemical compounds |
DK1114028T3 (da) | 1998-08-26 | 2007-04-30 | Aventis Pharma Ltd | Azabicykliske forbindelser, der modulerer inhibering af celleadhæsion |
GB9821199D0 (en) * | 1998-09-30 | 1998-11-25 | Glaxo Group Ltd | Chemical compounds |
US6207700B1 (en) * | 1999-01-07 | 2001-03-27 | Vanderbilt University | Amide derivatives for antiangiogenic and/or antitumorigenic use |
ATE325105T1 (de) | 1999-02-16 | 2006-06-15 | Aventis Pharma Ltd | Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden |
JP2000344666A (ja) | 1999-04-01 | 2000-12-12 | Sankyo Co Ltd | 糖及び脂質代謝改善剤 |
EP1183254B1 (en) | 1999-04-12 | 2005-01-12 | Aventis Pharma Limited | Substituted bicyclic heteroaryl compounds as integrin antagonists |
AU769652B2 (en) | 1999-05-05 | 2004-01-29 | Cubist Pharmaceuticals, Inc. | Novel prolines as antimicrobial agents |
AU4591600A (en) | 1999-05-05 | 2000-11-21 | Aventis Pharma Limited | Substituted bicyclic compounds |
ATE263162T1 (de) | 1999-05-05 | 2004-04-15 | Aventis Pharma Ltd | Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren |
CA2372836C (en) | 1999-05-05 | 2009-01-20 | Aventis Pharma Limited | Substituted pyrrolidines as cell adhesion inhibitors |
US6756378B2 (en) * | 1999-06-30 | 2004-06-29 | Pharmacopeia Drug Discovery, Inc. | VLA-4 inhibitor compounds |
JP2003503350A (ja) | 1999-06-30 | 2003-01-28 | 第一製薬株式会社 | Vla−4インヒビター化合物 |
CZ2002518A3 (cs) | 1999-08-13 | 2002-05-15 | Biogen, Inc. | Inhibitory buněčné adheze a farmaceutické prostředky, které je obsahují |
IL149544A0 (en) | 1999-11-10 | 2002-11-10 | Aventis Pharma Gmbh | N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR Xa |
NZ518886A (en) * | 1999-12-28 | 2004-02-27 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
GB0001346D0 (en) | 2000-01-21 | 2000-03-08 | Astrazeneca Uk Ltd | Chemical compounds |
DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
GB0004686D0 (en) | 2000-02-28 | 2000-04-19 | Aventis Pharma Ltd | Chemical compounds |
AU2001235806A1 (en) | 2000-03-01 | 2001-09-12 | Aventis Pharma Limited | 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
BR0112580A (pt) | 2000-07-19 | 2003-06-17 | Hoffmann La Roche | Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos, processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos |
GB2377933A (en) | 2001-07-06 | 2003-01-29 | Bayer Ag | Succinic acid derivatives useful as integrin antagonists |
-
2001
- 2001-12-28 WO PCT/JP2001/011641 patent/WO2002053534A1/ja active Application Filing
- 2001-12-28 TW TW090133464A patent/TWI312779B/zh not_active IP Right Cessation
- 2001-12-28 EP EP01272548A patent/EP1346982B1/en not_active Expired - Lifetime
- 2001-12-28 AT AT01272548T patent/ATE524441T1/de not_active IP Right Cessation
- 2001-12-28 BR BR0116608-5A patent/BR0116608A/pt not_active IP Right Cessation
- 2001-12-28 CA CA2430978A patent/CA2430978C/en not_active Expired - Fee Related
- 2001-12-28 CN CNB018214843A patent/CN100471838C/zh not_active Expired - Fee Related
- 2001-12-28 US US10/451,159 patent/US7157487B2/en not_active Expired - Fee Related
- 2001-12-28 IL IL15606401A patent/IL156064A0/xx unknown
- 2001-12-28 KR KR1020037008702A patent/KR100884877B1/ko not_active IP Right Cessation
- 2001-12-28 JP JP2002554653A patent/JP4212358B2/ja not_active Expired - Fee Related
- 2001-12-28 AU AU2002219555A patent/AU2002219555B2/en not_active Ceased
- 2001-12-28 RU RU2003123115/04A patent/RU2290403C2/ru active
- 2001-12-28 MX MXPA03005838A patent/MXPA03005838A/es active IP Right Grant
- 2001-12-28 AR ARP010106105A patent/AR035218A1/es unknown
-
2003
- 2003-06-27 NO NO20032994A patent/NO326014B1/no not_active IP Right Cessation
-
2004
- 2004-05-07 HK HK04103218.6A patent/HK1060726A1/xx not_active IP Right Cessation
-
2006
- 2006-02-08 HK HK06101636.2A patent/HK1081545A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1060726A1 (en) | 2004-08-20 |
US20040110945A1 (en) | 2004-06-10 |
AR035218A1 (es) | 2004-05-05 |
HK1081545A1 (en) | 2006-05-19 |
CN100471838C (zh) | 2009-03-25 |
ATE524441T1 (de) | 2011-09-15 |
EP1346982A4 (en) | 2005-08-10 |
CN1483024A (zh) | 2004-03-17 |
NO20032994L (no) | 2003-08-27 |
IL156064A0 (en) | 2003-12-23 |
MXPA03005838A (es) | 2003-09-10 |
EP1346982B1 (en) | 2011-09-14 |
AU2002219555B2 (en) | 2006-11-30 |
KR100884877B1 (ko) | 2009-02-23 |
JPWO2002053534A1 (ja) | 2004-04-30 |
CA2430978C (en) | 2012-05-15 |
WO2002053534A8 (fr) | 2002-09-19 |
RU2290403C2 (ru) | 2006-12-27 |
KR20030067730A (ko) | 2003-08-14 |
RU2003123115A (ru) | 2005-03-27 |
NO20032994D0 (no) | 2003-06-27 |
EP1346982A1 (en) | 2003-09-24 |
TWI312779B (pt) | 2009-08-01 |
US7157487B2 (en) | 2007-01-02 |
CA2430978A1 (en) | 2002-07-11 |
NO326014B1 (no) | 2008-09-01 |
WO2002053534A1 (fr) | 2002-07-11 |
JP4212358B2 (ja) | 2009-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0116608A (pt) | Inibidores vla-4 | |
BRPI0510394A (pt) | inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 | |
BRPI0513990A (pt) | composições de silano, processos para suas preparações e composições de borracha contendo as mesmas | |
BR0114253A (pt) | Antagonistas de receptor de glutamato metabotrópico | |
BR0012647A (pt) | Composto, processo de preparação do mesmo, produto, composição farmacêutica, e utilização do produto | |
BRPI0514448A (pt) | derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias | |
BR9913592A (pt) | Compostos, processo de preparação dos compostos, e, composições farmacêuticas | |
BRPI0413490A (pt) | novos compostos | |
BR0214344A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
BRPI0013667B8 (pt) | derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos e seus intermediários na produção deles | |
BR9813938A (pt) | Compostos terapeuticamente ativos baseados na substituição bioisóstera de indazol por catecol em inibidores de pde4 | |
BRPI0518533A2 (pt) | 18-metil-19-nor-pregn-4-en-21,17- carbolactona, bem como preparados farmacÊuticos contendo as mesmas | |
BRPI0315143B8 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BR0113180A (pt) | Composto de acilacetonitrila, processo para sua preparação e miticida contendo o mesmo | |
EA200870433A1 (ru) | Азагетероциклильные производные андростанов и андростенов в качестве лекарственных средств от сердечно-сосудистых расстройств | |
NO971384D0 (no) | Pyrimidinylpyrazol-derivat | |
CA2118102A1 (fr) | Nouveaux derives de 1,2,3,4-tetrahydronaphtalene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
BR0306838A (pt) | Peptìdeo não-nativo, ácido nucléico isolado, composição farmacêutica e kit para prevenção ou tratamento de uma doença modulada por crf2r | |
DE69841852D1 (de) | Verfahren zur Herstellung von monofunktionalisiertem 1,4,7,10-Tetraazacyclododecan | |
BR0014615A (pt) | Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b | |
BR0100107A (pt) | Compostos de benzenossulfonamida, um processo para sua preparação e composições farmacêuticas que contêm os mesmos | |
CA2334821A1 (en) | Chemical synthesis of morpholine derivatives | |
EA200701868A1 (ru) | Производные аминобутановой кислоты, ингибирующие cpt | |
BRPI0601725A (pt) | compostos de fenilpiridilpiperazina, um processo para sua preparação e composições farmacêuticas contendo-os | |
WO2007004090A3 (en) | Improved processes for the preparation of purified solanesol, solanesyl bromide and solanesyl acetone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: C07D 209/42, C07D 263/58, C07D 401/12, C07D 401/14, C07D 403/06, C07D 403/12, C07D 413/12, C07D 413/14, C07D 417/06, C07D 417/12, C07D 471/04, C07D 491/056, A61K 31/404, A61K 31/423, A61K 31/428, A61K 31/4439, A61K 31/496, A61K 31/54, A61K 31/472, A61P 29/00 Ipc: C07D 209/42 (2011.01), C07D 263/58 (2011.01), C07D |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2286 DE 29/10/2014. |